Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Haemophilia A Stories

2013-12-03 08:31:26

Full article: http://bit.ly/EpiVax_Biotest DREIEICH, Germany and PROVIDENCE, R.I., Dec. 3, 2013 /PRNewswire/ -- Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by...

2013-10-15 23:34:20

Dr. Gary McClain is speaking at a family camp for children with hemophilia and active inhibitors and their families on October 17-20 at Victory Junction in Randleman, NC. (PRWEB) October 15, 2013 Dr. Gary McClain is speaking at a family camp for children with hemophilia and active inhibitors and their families on October 17-20 at Victory Junction in Randleman, NC. A specialist in the emotional and spiritual impact of chronic and catastrophic illnesses, Gary McClain, PhD, developed...

2013-02-28 08:31:17

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency KING OF PRUSSIA, Pa., Feb. 28, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact(®), Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital...

2012-09-10 22:23:11

LONDON and MOSCOW, September 11, 2012 /PRNewswire/ -- Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous...

2012-09-09 22:24:27

LONDON and MOSCOW, September 10, 2012 /PRNewswire/ -- Pro Bono Bio Group plc ("PBB"), the international healthcare group, and PolyTherics Limited ("PolyTherics"), a provider of solutions for the development of better biopharmaceuticals, announce further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. Following an agreement between the parties in May 2012, PBB and PolyTherics undertook a feasibility programme to evaluate...

2012-06-25 02:26:26

BEIJING, June 25, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang") has received a manufacturing approval certificate from the China State Food and Drug Administration ("SFDA") for Human Coagulation Factor VIII ("FVIII"). With this...

2011-05-19 15:00:00

KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL). CSL627, a unique single-chain recombinant...

2011-05-17 18:00:00

KING OF PRUSSIA, Pa., May 17, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX: CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases." (Logo:...

2011-02-18 14:57:00

KING OF PRUSSIA, Pa., Feb. 18, 2011 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact(TM), Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S....

2010-11-15 20:33:09

The use of recombinant activated factor 7 (rFVIIa) "“ a drug used to treat bleeding in hemophiliacs "“ in patients without hemophilia is not recommended because of the potential for adverse events, found a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100408.pdf. Recombinant activated factor 7 is a hemostatic agent licensed for the treatment of bleeding in hemophilia patients. It is also used "off-label" for...